EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mitochondrial Pyruvate Carrier 1 as a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer

Hongbo Zou, Yunfei Yin, Kai Xiong, Xuelian Luo, Zhongju Sun, Bijing Mao, Qichao Xie, Mei Tan, Rui Kong iD

Technology in Cancer Research & Treatment · 2024

DOI: 10.1177/15330338241282080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Hongbo Zou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Monocarboxylic Acid Transporters, Biomarkers, Tumor, Mitochondrial Membrane Transport Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Third Affiliated Hospital of Chongqing Medical University Scientific Research Incubation Project Youth Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Abnormal mitochondrial pyruvate carrier 1 (MPC1) expression plays a key role in tumor metabolic reprogramming and progression. Understanding its significance in non-small cell lung cancer (NSCLC) is crucial for identifying therapeutic targets.

Methods

TIMER 2.0 was utilized to assess the expression of MPC1 in both normal and cancer tissues in pan-cancer. Overall survival (OS) differences between high and low MPC1 expression were analyzed in NSCLC using the Cancer Genome Atlas (TCGA) datasets. We also examined the expression of MPC1 in NSCLC cell lines using western blotting and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). In addition, the tissue samples and clinical information of 80 patients with NSCLC from our hospital were collected. Immunohistochemistry (IHC) was used to assess MPC1 expression, and OS was evaluated using Kaplan-Meier curves and the log-rank test. Univariate and multivariate Cox regression analyses were conducted to evaluate the prognostic values of the clinical characteristics and MPC1expression.

Results

Analysis of public databases suggested that MPC1 was downregulated in NSCLC compared to that in normal lung tissue and predicted poor prognosis. In addition, the expression of MPC1 in NSCLC cell lines was lower than that in human bronchial epithelial (HBE) cells at both protein and mRNA levels. Further clinical analysis suggested that MPC1 expression was correlated with age, tumor T stage, and TNM stage. Kaplan-Meier analysis revealed that NSCLC patients with high MPC1 expression had a better prognosis, particularly in lung adenocarcinoma (LUAD), whereas no survival benefit was observed in lung squamous cell carcinoma (LUSC). Univariate and multivariate analyses suggested that MPC1 was an independent prognostic factor for patients with NSCLC.

Conclusions

MPC1 is poorly expressed in NSCLC, particularly in LUAD, which predicts a poor prognosis and may serve as an independent prognostic factor. Further studies on MPC1 may reveal new targets for the treatment of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungMonocarboxylic Acid TransportersBiomarkers, TumorMitochondrial Membrane Transport ProteinsLung NeoplasmsKaplan-Meier EstimateHumansPrognosisFemaleMaleMiddle AgedCell Line, TumorGene Expression Regulation, NeoplasticAgedImmunohistochemistryNeoplasm Staging

Stichwörter der Autor:innen

lung adenocarcinoma (LUAD)mitochondrial pyruvate carrier 1 (MPC1)non-small cell lung cancer (NSCLC)overall survival (OS)prognosis

Substanzen

MPC1 protein, humanMonocarboxylic Acid TransportersBiomarkers, TumorMitochondrial Membrane Transport Proteins

Autor:innen und Institutionen

  • Department of Oncology, the Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), Chongqing, China.
  • Department of Oncology, Chongqing Beibei District Traditional Chinese Medicine Hospital, Chongqing, China.
  • Department of Pharmacy, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei, China.

ORCID-Profile: Rui Kong

Förderung

  • The Third Affiliated Hospital of Chongqing Medical University Scientific Research Incubation Project Youth Project

Zitieren

APA

Zou, H., Yin, Y., Xiong, K., Luo, X., Sun, Z., Mao, B., Xie, Q., Tan, M., & Kong, R. (2024). Mitochondrial Pyruvate Carrier 1 as a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241282080

Vancouver

Zou H, Yin Y, Xiong K, Luo X, Sun Z, Mao B, et al. Mitochondrial Pyruvate Carrier 1 as a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241282080

BibTeX
@article{Zou2024,
  author = {Zou, Hongbo and Yin, Yunfei and Xiong, Kai and Luo, Xuelian and Sun, Zhongju and Mao, Bijing and Xie, Qichao and Tan, Mei and Kong, Rui},
  title = {Mitochondrial Pyruvate Carrier 1 as a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer},
  journal = {Technology in Cancer Research & Treatment},
  year = {2024},
  doi = {10.1177/15330338241282080}
}
Kostenlos starten →